Tadaaki Yamada - Concepedia

Author

Tadaaki Yamada

Also Known As

T Yamada, T. Yamada, T., Yamada, TADAAKI YAMADA, Tadaaki YAMADA, Tadaaki Yamada, Tadaaki Yamada (412405), Yamada Tadaaki, Yamada, Tadaaki

557

Publications

Citations

H-Index

Concepts

All Affiliations

Kanazawa University Kyoto Prefectural University of Medicine Kyoto first Red Cross hospital Tokushima University Japanese Red Cross Society Kyoto Daini Hospital

About

Tadaaki Yamada is an author at Kanazawa University specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	36	1.5K
2	Health Sciences	3	3	175
3	Biochemistry	2	2	88
4	Engineering	1	1	30
5	Social Sciences	1	1	37

Tadaaki Yamada

114

Publications

Citations

H-Index

Page 1

	Year	Citations
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Nature Communications	2019	351
Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Wei Wang, Qi Li, Tadaaki Yamada, Clinical Cancer Research	2009	295
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort Seiji Yano, Tadaaki Yamada, Shinji Takeuchi, Journal of Thoracic Oncology Acquired ResistanceMedicineKinase InhibitorsPathologyBronchial Neoplasm	2011	217
EGFR-TKI Resistance Due to <i>BIM</i> Polymorphism Can Be Circumvented in Combination with HDAC Inhibition Takayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, Cancer Research Bim FunctionGeneticsHuman PolymorphismPathologyMolecular Genetics	2013	155
Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials M. Hale, James Wild, Jyotsna Reddy, The Lancet. Gastroenterology & hepatology Opioid EpidemicParallel-group TrialsPhase 3Health SciencesPain Medicine	2017	124
Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells Tadaaki Yamada, Shinji Takeuchi, Junya Nakade, Clinical Cancer Research	2012	116
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer Tadaaki Yamada, Soichi Hirai, Yuki Katayama, Cancer Medicine	2019	114
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer Rong Wang, Tadaaki Yamada, Kenji Kita, Nature Communications	2020	112
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in <i>EGFR</i> Mutant Lung Cancer Ivan Donev, Wei Wang, Tadaaki Yamada, Clinical Cancer Research	2011	109
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Clinical Cancer Research	2020	108

Page 1